financetom
Business
financetom
/
Business
/
Thomson Reuters' AI Integration to Drive Price Increases and Retention, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Thomson Reuters' AI Integration to Drive Price Increases and Retention, UBS Says
Mar 14, 2024 12:54 PM

03:38 PM EDT, 03/14/2024 (MT Newswires) -- Thomson Reuters' ( TRI ) AI-embedded workflows will support price increases and improve retention, UBS said in a note Thursday.

The investment firm said Reuters' short-term and long-term guidance seems conservative given the increase in generative artificial intelligence integration, launch, and monetization in 2024.

The market is realizing a significant change in the underlying structure of Reuters' business model to factor in the shift to cloud-based operations from traditional service offerings, according to the note.

UBS said Reuters plans to drive cross-selling opportunities by consolidating its AI legal tools into a single product and enhancing user retention with experts refining AI models and curating databases.

The company's potential retention improvement enhances its attractiveness, the firm added.

UBS reiterated its buy rating on Reuters and kept the price target at $177.

Price: 157.00, Change: +0.60, Percent Change: +0.38

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novartis loses bid to block US Entresto generic through 2026
Novartis loses bid to block US Entresto generic through 2026
Jul 11, 2025
July 11 (Reuters) - Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto through late 2026, a Delaware federal judge said on Friday. U.S. District Judge Richard Andrews rejected Novartis' argument that MSN's generic would infringe one of its patents and denied its request to block the generic from launching until after...
Why Is Milestone Pharmaceuticals Stock Plunging On Friday?
Why Is Milestone Pharmaceuticals Stock Plunging On Friday?
Jul 11, 2025
Milestone Pharmaceuticals Inc. ( MIST ) moved closer to potential FDA approval for its Cardamyst (etripamil) nasal spray, an investigational therapy for paroxysmal supraventricular tachycardia (PSVT), as the U.S. Food and Drug Administration (FDA) accepted the company’s response to prior issues. However, shares of Milestone Pharmaceuticals ( MIST ) plummeted over 36% on Friday following the pricing of a public...
--CEL-SCI Shares Halted, Pending Material News Release
--CEL-SCI Shares Halted, Pending Material News Release
Jul 11, 2025
12:07 PM EDT, 07/11/2025 (MT Newswires) -- Price: 5.08, Change: +1.26, Percent Change: +32.98 ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved